id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-D-3101-0011,FDA,FDA-2017-D-3101,Abbreviated New Drug Applications: Pre-Submission of Facility  Information Related to Prioritized Generic Drug Applications (Pre-Submission Facility Correspondence); Draft Guidance for Industry;  Availability,Notice,Guidance,2017-11-06T05:00:00Z,2017,11,2017-11-06T05:00:00Z,2018-02-06T04:59:59Z,2017-11-06T14:47:02Z,2017-24099,0,0,0900006482c48219
FDA-2017-D-3101-0012,FDA,FDA-2017-D-3101,ANDAs: Pre-Submission of Facility Information Related to Prioritized Generic Drug Applications (Pre-Submission Facility Correspondence) Guidance for Industry,Other,Guidance,2017-11-06T04:00:00Z,2017,11,2017-11-06T04:00:00Z,2018-02-06T04:59:59Z,2025-06-16T18:01:07Z,,0,0,0900006482c4b344
FDA-2017-D-3101-0002,FDA,FDA-2017-D-3101,"ANDAs: Pre-Submission Facility Correspondence Associated with Priority
Submissions Guidance for Industry",Other,Guidance,2017-06-20T04:00:00Z,2017,6,2017-06-20T04:00:00Z,2017-09-19T03:59:59Z,2019-06-18T16:16:08Z,,0,0,09000064826f71e8
FDA-2017-D-3101-0001,FDA,FDA-2017-D-3101,"Abbreviated New Drug Applications: Pre-Submission Facility  Correspondence Associated with Priority Submissions; Draft Guidance
for Industry; Availability",Notice,Notice of Availability,2017-06-20T04:00:00Z,2017,6,2017-06-20T04:00:00Z,2017-09-19T03:59:59Z,2017-06-30T13:04:39Z,2017-12836,0,0,09000064826f5d6c